Scientific Sessions 2025  /  Multimorbidity: Hypertension, Hyperlipidemia and Cardiovascular Disease  /  Discuss Case Study 1 in Breakout Groups
Logo

American Heart Association

  41
  0

Final ID:

Discuss Case Study 1 in Breakout Groups

  • Joseph, Joshua  ( The Ohio State University COM , Columbus , Ohio , United States )
  • Khan, Sadiya  ( Northwestern University , Chicago , Illinois , United States )
  • Ndumele, Chiadi  ( JOHNS HOPKINS HOSPITAL , Silver Spring , Maryland , United States )
  • Lala-trindade, Anuradha  ( MOUNT SINAI HOSPITAL , New York , New York , United States )
  • Vest, Amanda  ( Cleveland Clinic Ohio , Cleveland , Ohio , United States )
  • Vardeny, Orly  ( Minneapolis VA Health Care System , Minneapolis , Minnesota , United States )
  • Powell-wiley, Tiffany  ( NATIONAL INSTITUTES OF HEALTH , Silver Spri , Maryland , United States )
  • Modarressi, Taher  ( Advocare Princeton Cardiometabolic Health , Pennington , New Jersey , United States )
  • Pagidipati, Neha  ( DCRI , Durham , North Carolina , United States )
  • Magwire, Melissa  ( Cardiometabolic Center Alliance , Kansas City , Missouri , United States )
  • Rangaswami, Janani  ( George Washington University , Falls Church , Virginia , United States )
    • Author Disclosures:
    Joshua Joseph: DO NOT have relevant financial relationships | Sadiya Khan: DO NOT have relevant financial relationships | Chiadi Ndumele: DO NOT have relevant financial relationships | Anuradha Lala-Trindade: No Answer | Amanda Vest: DO have relevant financial relationships ; Research Funding (PI or named investigator):CareDx:Past (completed) | Orly Vardeny: DO have relevant financial relationships ; Research Funding (PI or named investigator):AstraZeneca:Active (exists now) ; Advisor:Moderna:Past (completed) ; Consultant:Cytokinetics:Active (exists now) ; Consultant:Novonordisk:Active (exists now) ; Advisor:Cardior:Past (completed) ; Research Funding (PI or named investigator):Cardurion:Active (exists now) ; Research Funding (PI or named investigator):Bayer:Active (exists now) | Tiffany Powell-Wiley: DO NOT have relevant financial relationships | Taher Modarressi: DO have relevant financial relationships ; Advisor:Novo Nordisk:Active (exists now) ; Speaker:AstraZeneca:Past (completed) ; Speaker:Madrigal Pharmaceuticals:Active (exists now) ; Speaker:Abbott:Active (exists now) ; Speaker:Amgen:Active (exists now) ; Speaker:Eli Lilly:Active (exists now) ; Research Funding (PI or named investigator):Eli Lilly:Active (exists now) ; Research Funding (PI or named investigator):Amgen:Active (exists now) ; Research Funding (PI or named investigator):AstraZeneca:Active (exists now) ; Consultant:CRISPR Therapeutics:Past (completed) ; Consultant:Novo Nordisk:Active (exists now) ; Advisor:Eli Lilly:Active (exists now) ; Advisor:Regeneron:Active (exists now) ; Advisor:New Amsterdam:Active (exists now) ; Advisor:Novartis:Active (exists now) | Neha Pagidipati: DO have relevant financial relationships ; Research Funding (PI or named investigator):Alnylam:Active (exists now) ; Consultant:Esperion:Active (exists now) ; Consultant:Eli Lilly:Active (exists now) ; Consultant:Corsera:Active (exists now) ; Consultant:Corcept:Active (exists now) ; Consultant:Boehringer Ingelheim:Active (exists now) ; Consultant:Bayer:Active (exists now) ; Consultant:Amgen:Active (exists now) ; Research Funding (PI or named investigator):Merck:Active (exists now) ; Research Funding (PI or named investigator):Novo Nordisk:Active (exists now) ; Research Funding (PI or named investigator):Novartis:Active (exists now) ; Research Funding (PI or named investigator):Eli Lilly:Active (exists now) ; Research Funding (PI or named investigator):Boehringer Ingelheim:Active (exists now) ; Research Funding (PI or named investigator):Bayer:Active (exists now) ; Research Funding (PI or named investigator):Amgen:Active (exists now) | Melissa Magwire: DO have relevant financial relationships ; Advisor:NNI :Active (exists now) ; Consultant:BI :Active (exists now) | Janani Rangaswami: DO have relevant financial relationships ; Consultant:Boehringer Ingelheim:Active (exists now) ; Consultant:Procyrion:Active (exists now) ; Consultant:Bayer:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Multimorbidity: Hypertension, Hyperlipidemia and Cardiovascular Disease

Friday, 11/07/2025 , 03:10PM - 04:00PM

Cardiovascular Seminar

More abstracts on this topic:
Case Study 1 Facilitiation for Multimorbidity: Hypertension, Hyperlipidemia and Cardiovascular Disease

Plutzky Jorge

More abstracts from these authors:
Obtaining access to cardioprotective anti-hyperglycemic therapies to promote CKM health

Joseph Joshua, Modarressi Taher

Introduction and Application of the PREVENT Risk Calculator

Ndumele Chiadi, Khan Sadiya, Powell-wiley Tiffany

You have to be authorized to contact abstract author. Please, Login
Not Available